Advertisement
UK markets close in 8 hours 3 minutes
  • FTSE 100

    7,846.93
    -30.12 (-0.38%)
     
  • FTSE 250

    19,323.71
    -126.96 (-0.65%)
     
  • AIM

    741.87
    -3.42 (-0.46%)
     
  • GBP/EUR

    1.1677
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2439
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    51,947.25
    +2,645.00 (+5.36%)
     
  • CMC Crypto 200

    1,334.83
    +22.20 (+1.69%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.70
    +0.97 (+1.17%)
     
  • GOLD FUTURES

    2,405.40
    +7.40 (+0.31%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,228.40
    -157.47 (-0.96%)
     
  • DAX

    17,679.25
    -158.15 (-0.89%)
     
  • CAC 40

    7,976.91
    -46.35 (-0.58%)
     

How Novartis’s Valuation Compares

How Novartis’s Valuation Compares

Healthcare giant Novartis (NVS) researches, develops, manufactures, and commercializes pharmaceutical products. Novartis surpassed analysts’ revenue and EPS estimates during Q1 2018, with its revenue growing 4% year-over-year to $12.7 billion from $11.5 billion at constant exchange rates. Foreign exchange boosted its revenue by 6%.